Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (211-220 of 390) with videos related to

Pageof 39
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2024
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple SclerosisJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Therapeutic Advances in Neurological Disorders|February 28, 2024
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapiesHelmut Butzkueven, Tomas Kalincik, Francesco Patti, et al.
Journal of Neuroimmunology|August 14, 2025
Neurotoxicity associated with chimeric antigen receptor T-cell therapyMiriam Wronski, Robb Wesselingh, Christina Kazzi, et al.
Immunology and Cell Biology|June 14, 2024
Transcriptional network analysis of peripheral blood leukocyte subsets in multiple sclerosis identifies a pathogenic role for a cytotoxicity-associated gene network in myeloid cellsMargaret A Jordan, Melissa M Gresle, Adrian T Gemiarto, et al.
European Journal of Neurology|December 23, 2024
Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Multiple Sclerosis and Related Disorders|December 15, 2020
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemicLouise Rath, Minh Viet Bui, Julian Ellis, et al.
Brain : a Journal of Neurology|February 4, 2026
Optimal strategies for treatment discontinuation in MOG antibody-associated diseaseWei Z Yeh, Anna Francis, Sarah Cooper, et al.
Neurology|May 31, 2015
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSLudwig Kappos, Ernst-Wilhelm Radue, Giancarlo Comi, et al.
European Journal of Neurology|April 23, 2022
Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis ConsortiumSarah Griffith, Robb Wesselingh, James Broadley, et al.
Neurology|August 4, 2023
Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple SclerosisVicki Maltby, Alexandre Xavier, Ewoud Ewing, et al.
Pageof 39

Showing results (211-220 of 390) with videos related to

Sort By:
Pageof 39
Neurology(R) Neuroimmunology & Neuroinflammation|October 11, 2024
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple SclerosisJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Therapeutic Advances in Neurological Disorders|February 28, 2024
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapiesHelmut Butzkueven, Tomas Kalincik, Francesco Patti, et al.
Journal of Neuroimmunology|August 14, 2025
Neurotoxicity associated with chimeric antigen receptor T-cell therapyMiriam Wronski, Robb Wesselingh, Christina Kazzi, et al.
Immunology and Cell Biology|June 14, 2024
Transcriptional network analysis of peripheral blood leukocyte subsets in multiple sclerosis identifies a pathogenic role for a cytotoxicity-associated gene network in myeloid cellsMargaret A Jordan, Melissa M Gresle, Adrian T Gemiarto, et al.
European Journal of Neurology|December 23, 2024
Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosisYi Chao Foong, Daniel Merlo, Melissa Gresle, et al.
Multiple Sclerosis and Related Disorders|December 15, 2020
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemicLouise Rath, Minh Viet Bui, Julian Ellis, et al.
Brain : a Journal of Neurology|February 4, 2026
Optimal strategies for treatment discontinuation in MOG antibody-associated diseaseWei Z Yeh, Anna Francis, Sarah Cooper, et al.
Neurology|May 31, 2015
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSLudwig Kappos, Ernst-Wilhelm Radue, Giancarlo Comi, et al.
European Journal of Neurology|April 23, 2022
Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis ConsortiumSarah Griffith, Robb Wesselingh, James Broadley, et al.
Neurology|August 4, 2023
Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple SclerosisVicki Maltby, Alexandre Xavier, Ewoud Ewing, et al.
Pageof 39